GP方案治疗晚期非小细胞肺癌临床疗效观察  

Curative of Gemcitabine Combined with Cisplatin for Advanced Non-Small Cell Lung Cancer

作　　者：钱和生[1] 胡勇[1] 郭兴来 

机构地区：[1]安徽省阜阳市肿瘤医院化疗科,236000

出　　处：《中华全科医学》2009年第8期813-814,共2页Chinese Journal of General Practice

摘　　要：目的评价国产吉西他滨(GEM)联合顺铂(DDP)治疗晚期非小细胞肺癌的临床疗效及不良反应。方法39例晚期非小细胞肺癌患者应用吉西他滨联合顺铂化疗,吉西他滨1000mg/m2,静脉滴注30min,d1,8;DDP30mg/m2,静脉滴注,d2～4,21d为1周期,化疗2～3周期后评价疗效。结果39例患者中,1例CR,15例PR,17例SD,6例PD,总有效率(CR+PR)为41.0%。鳞癌有效率为38.5%;腺癌有效率为42.3%;Ⅲb期有效率为47.6%,Ⅳ期有效率为33.3%;主要毒副反应为骨髓抑制和胃肠道反应,其中白细胞下降至Ⅲ度者为15.4%,血小板下降至Ⅲ、Ⅳ度者为20.5%,Ⅲ度以上恶心呕吐的发生率为7.7%。结论国产吉西他滨联合顺铂治疗晚期非小细胞肺癌疗效较好,毒副反应较轻,患者耐受良好,值得临床推广。Objective To evaluate the efficacy and toxicities of gemeitabine combined with cisplatin for advanced non-small cell lung cancer. Methods Thirty-nine patients with advanced non-small cell lung cancer received combined chemotherapy： gemcitabine 1 000 mg/m^2 , infusion during 30 minutes on day 1,8, cisplatin 30 mg/m^2 intravenous drip day 2 to 4. The treatment course was 21 days. Results One case achieved CR and 15 achieved PR, 17 SD and 6 PD. The overall response rate（ CR ＋ PR） was 41.0% The effective rate were 38.5% for squamous cell carcinoma and 42.3% for adenocarcinoma;47.6% in Ⅲb stage, and 33.3% in Ⅳ stage. The main toxicities were myelotoxicity and gastrointestinal reaction, in which grade Ⅲ neutropenia accounted for 15. 4% , grade m-Ⅳ thrombocytopenia for 20. 5% , and grade Ⅲ or more nausea and vomiting for 7. 7%. Conclusion Combination chemotherapy of gemcitabine and eisplatin has a good anti-tumor activity on advanced non-small cell lung cancer with manageable toxicity.

关 键 词：肺肿瘤 非小细胞 吉西他滨 顺铂 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]